Waldenström macroglobulinemia:a challenging case treated with anti-CD19 CAR-T cell therapy  

作　　者：Yang YANG Xiaolin GU Jingsong HE Yongxian HU Zhen CAI 

机构地区：[1]Bone Marrow Transplantation Center,Department of Hematology,the First Affiliated Hospital,School of Medicine,Zhejiang University,Hangzhou 310006,China [2]Department of Hematology,Putuo People’s Hospital,Zhoushan 316100,China

出　　处：《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》2024年第8期719-722,共4页浙江大学学报（英文版）B辑（生物医学与生物技术）

基　　金：supported by the Zhejiang Key Research and Development Project(No.2020C03014).

摘　　要：Waldenström macroglobulinemia(WM)is characterized by lymphoplasmacytic lymphoma associated with large amounts of monoclonal immunoglobulin M(IgM)protein(Owen et al.,2003).Common signs and symptoms include fatigue due to anemia,lymph node enlargement,hepatosplenomegaly,thrombocytopenia,symptoms related to high viscosity,and peripheral neuropathy,among others.Despite significant advances in WM treatment,this type of indolent lymphoma remains incurable,with a wide array of patient outcomes(Ruan et al.,2020).In recent years,chimeric antigen receptor T(CAR-T)cell therapy targeting cluster of differentiation 19(CD19)has shown unprecedented response rates and durability in the treatment of B-cell malignancies.In this report,we describe a challenging case of WM that involved multiple extramedullary sites,relapsed,and was refractory to chemotherapy,immunotherapy,and targeted therapy.After anti-CD19 CAR-T cell therapy,the tumor burden significantly decreased and the patient’s condition remained stable at the writing of this report.

关 键 词：CD19 GLOBULIN DURABILITY 

分 类 号：R392[医药卫生—免疫学]